[{"id":"9d94409b-3124-4594-8d29-7cfddaf92a43","acronym":"FOENIX-CCA4","url":"https://clinicaltrials.gov/study/NCT05727176","created_at":"2023-02-14T18:02:28.005Z","updated_at":"2025-02-25T17:02:23.376Z","phase":"Phase 2","brief_title":"Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement","source_id_and_acronym":"NCT05727176 - FOENIX-CCA4","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 07/05/2023","start_date":" 07/05/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-03"},{"id":"eb57432c-2617-48dd-9e9e-25c0afd719ac","acronym":"CIBI375A201","url":"https://clinicaltrials.gov/study/NCT04256980","created_at":"2021-01-19T19:16:58.237Z","updated_at":"2024-07-02T16:35:00.136Z","phase":"Phase 2","brief_title":"Pemigatinib in Treating Patients With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Rearrangement","source_id_and_acronym":"NCT04256980 - CIBI375A201","lead_sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 03/03/2020","start_date":" 03/03/2020","primary_txt":" Primary completion: 01/29/2021","primary_completion_date":" 01/29/2021","study_txt":" Completion: 08/31/2023","study_completion_date":" 08/31/2023","last_update_posted":"2024-05-30"},{"id":"23311617-41c6-44fc-9230-357b9b804a7b","acronym":"FIGHT-302","url":"https://clinicaltrials.gov/study/NCT03656536","created_at":"2021-01-19T16:33:21.014Z","updated_at":"2024-07-02T16:35:02.376Z","phase":"Phase 3","brief_title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma","source_id_and_acronym":"NCT03656536 - FIGHT-302","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Pemazyre (pemigatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 434","initiation":"Initiation: 06/03/2019","start_date":" 06/03/2019","primary_txt":" Primary completion: 10/26/2027","primary_completion_date":" 10/26/2027","study_txt":" Completion: 07/27/2028","study_completion_date":" 07/27/2028","last_update_posted":"2024-05-21"},{"id":"b2993259-256a-4604-9f68-777de564f0ad","acronym":"FOENIX-CCA2","url":"https://clinicaltrials.gov/study/NCT02052778","created_at":"2021-01-17T17:33:24.806Z","updated_at":"2024-07-02T16:35:13.841Z","phase":"Phase 1/2","brief_title":"A Study of TAS-120 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT02052778 - FOENIX-CCA2","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR3 mutation • FGFR fusion • FGFR2 rearrangement • FGFR3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Completed","enrollment":" Enrollment 407","initiation":"Initiation: 07/21/2014","start_date":" 07/21/2014","primary_txt":" Primary completion: 10/01/2020","primary_completion_date":" 10/01/2020","study_txt":" Completion: 05/29/2021","study_completion_date":" 05/29/2021","last_update_posted":"2024-03-20"},{"id":"7081cc15-ba4e-458b-8ca4-38802c059b4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04507503","created_at":"2021-01-19T20:11:47.503Z","updated_at":"2024-07-02T16:35:17.897Z","phase":"","brief_title":"Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements","source_id_and_acronym":"NCT04507503","lead_sponsor":"Taiho Oncology, Inc.","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lytgobi (futibatinib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-02-23"},{"id":"1f885c20-bddc-441e-b3b3-ce916b0c4eaf","acronym":"FIGHT-209","url":"https://clinicaltrials.gov/study/NCT05267106","created_at":"2022-03-04T15:53:30.724Z","updated_at":"2024-07-02T16:35:22.897Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations","source_id_and_acronym":"NCT05267106 - FIGHT-209","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR1 mutation • FGFR fusion • FGFR2 rearrangement • FGFR1 fusion • FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/20/2022","start_date":" 05/20/2022","primary_txt":" Primary completion: 11/29/2024","primary_completion_date":" 11/29/2024","study_txt":" Completion: 11/29/2024","study_completion_date":" 11/29/2024","last_update_posted":"2024-01-19"},{"id":"2b64af10-d65b-4d9e-b123-5cd01fb9300a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627063","created_at":"2022-11-25T15:58:10.134Z","updated_at":"2024-07-02T16:35:38.335Z","phase":"Phase 1","brief_title":"A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05627063","lead_sponsor":"Abbisko Therapeutics Co, Ltd","biomarkers":" FGFR2","pipe":" | ","alterations":" FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C","tags":["FGFR2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 mutation • FGFR2 fusion • FGFR2 amplification • FGFR3 mutation • FGFR3 S249C • FGFR2 rearrangement • FGFR3 Y373C • FGFR3 G370C • FGFR3 R248C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABSK121"],"overall_status":"Recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 03/15/2025","primary_completion_date":" 03/15/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2023-09-01"},{"id":"89ca258d-eb1d-40cf-a834-fa6461b873b5","acronym":"FIGHT-202","url":"https://clinicaltrials.gov/study/NCT02924376","created_at":"2021-01-17T17:17:39.386Z","updated_at":"2024-07-02T16:35:54.862Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)","source_id_and_acronym":"NCT02924376 - FIGHT-202","lead_sponsor":"Incyte Corporation","biomarkers":" FGFR2 • FGFR","pipe":" | ","alterations":" FGFR2 fusion • FGFR2 rearrangement","tags":["FGFR2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR2 fusion • FGFR2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Pemazyre (pemigatinib)"],"overall_status":"Completed","enrollment":" Enrollment 147","initiation":"Initiation: 01/16/2017","start_date":" 01/16/2017","primary_txt":" Primary completion: 02/01/2022","primary_completion_date":" 02/01/2022","study_txt":" Completion: 02/01/2022","study_completion_date":" 02/01/2022","last_update_posted":"2023-02-23"}]